At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 157 enrolled
Drug / intervention
Ruxolitinib cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Dose-Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo
In Brief
A Phase 2 clinical trial evaluating Ruxolitinib cream and Vehicle cream for Vitiligo. Completed, enrolled 157 participants across 26 sites.
Detailed Summary
The purpose of this study will be to examine the efficacy, safety, and tolerability of ruxolitinib cream in subjects with vitiligo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVitiligo
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedApr 2017
Enrollment StartJun 2017
Primary CompletionSep 2018
Study CompletionSep 2021
TodayJul 2026
First PostedApr 4, 2017
Enrollment StartJun 7, 2017
Primary CompletionSep 12, 2018
Study CompletionSep 8, 2021
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 9.2 years ago
Interventions
Ruxolitinib creamdrug
Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
Vehicle creamdrug
Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.